TickerTalks
Browse all tickers →
TickerTalks›$MMED
MMMMED

MiniMed Group, Inc. Common Stock

$MMED·$6.3B·Medical - Equipment & Services·Healthcare
$24.06+7.3%
Mentions · last 7 days
2026-08-26: 0 posts2026-08-27: 0 posts2026-08-28: 14 posts2026-08-29: 10 posts2026-08-30: 21 posts2026-08-31: 18 posts2026-09-01: 78 posts165
Price updated 12m ago·X counts updated 38m ago
MMMMED
$MMEDMiniMed Group, Inc. Common Stock
$24.06+7.31%165 posts
AI analysisFundamentalsVoices on X
Loading…

What it does

Plain-English summary of the business — what they sell and how they make money.

Medical device company designing and manufacturing insulin pumps and infusion consumables for diabetes management.

Industry overviewAI analysisGenerated by AI from underlying data

Where Medical - Equipment & Services sits in its cycle right now — and what that implies for $MMED.

Medical - Equipment & Services · Healthcare

Hospital utilization recovery post-COVID is sustaining equipment demand; GLP-1 weight-loss drugs are a long-term volume headwind for bariatric equipment. Imaging and monitoring technology upgrades are driven by value-based care reimbursement incentives.

Top industry ETF

$IHIiShares U.S. Medical Devices ETF
-13.0%YTD
-12.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-20.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-5.3%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-9.1%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.0%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.7Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-14.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
52.9%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Sep 1, 2026$0.12$0.12-3.3%
Q1 2026Jun 3, 2026$-0.68$-0.15-356.2%
Q1 2026Apr 17, 2026$-0.16$0.17-194.0%

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q4 FY25$837.0M—57.3%9.8%$-0.68$-226.0M
Q3 FY25$790.0M—45.8%-11.8%$-0.42$13.0M
Q4 FY24$724.0M—55.5%-28.2%$0.00$26.0M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY27$3.4B$3.4B – $3.4B$0.66$0.57 – $0.7510
FY28$3.7B$3.7B – $3.7B$0.69$0.41 – $0.7910
FY29$4.1B$4.0B – $4.2B$1.77$1.53 – $1.897
FY30$4.6B$4.5B – $4.6B$2.45$2.41 – $2.503
FY31$5.1B$5.0B – $5.1B$3.19$3.15 – $3.262

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.5.0×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.—Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+27.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.—Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 27.5M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today22.1% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β-3.715-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDSep 18-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KOfficer or director changeAug 58-K — Item 5.02: Officer or director change
3New insider — initial holdingsJul 63
3New insider — initial holdingsJul 63
3New insider — initial holdingsJul 63
8-KOfficer or director changeJun 298-K — Item 5.02: Officer or director change · Item 5.08 · Item 8.01: Other event
8-KPress release / Reg FDJun 38-K — Item 2.02: Earnings release · Item 7.01: Press release / Reg FD
8-KOfficer or director changeMay 188-K — Item 5.02: Officer or director change
+ 26 other (14 3s · 4 8-Ks · 2 proxys · 1 ARS) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

MiniMed Group, Inc. (MMED) Q1 2027 Earnings Call Transcriptseekingalpha.com·1d agoMiniMed Group Q1 Earnings Call Highlightsmarketbeat.com·1d agoMiniMed Delivers Strong Start to Fiscal Year 2027 with U.S. Growth Accelerationprnewswire.com·2d agoTop Wall Street Forecasters Revamp MiniMed Group Expectations Ahead Of Q1 Earningsbenzinga.com·6d agoMiniMed to Participate in Upcoming Investor Conferencesprnewswire.com·8d ago

More in Medical - Equipment & Services

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$LAB$HIMS$LNSR$OMCL
Voices on X · top 1 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport